Basic Information
| LncRNA/CircRNA Name | LINC00261 |
| Synonyms | LINC00261, ALIEN, C20orf56, DEANR1, HCCDR1, NCRNA00261, onco-lncRNA-17 |
| Region | GRCh38_20:22547671-22578642 |
| Ensemble | ENSG00000259974 |
| Refseq | NR_001558 |
Classification Information
| Regulatory Mechanism | Biological Function | Clinical Application | |||
|---|---|---|---|---|---|
| TF | Immune | Survival | |||
| Enhancer | Apoptosis | Drug | Cisplatin | ||
| Variant | Cell Growth | Circulating | |||
| MiRNA | EMT | Metastasis | |||
| Methylation | Coding Ability | Recurrence |
Cancer&Entry Information
| Cancer Name | colon cancer |
| ICD-0-3 | C18 |
| Methods | qPCR, Western blot |
| Sample | colon cancer tissues, cell lines (HCT116, HCT8, HT29, SW480, FHC) |
| Expression Pattern | down-regulated |
| Function Description | LINC00261 overexpression might relieve cisplatin resistance of colon cancer cells via promoting cell apoptosis, and inhibiting cell viability,migration, and invasion.LINC00261 might down-regulate nuclear B-catenin through restraining B-catenin from cytoplasm into nuclei or it could also promote B-catenin degradation and inhibit activation of Wnt pathway.LINC00261 reduced cisplatin resistance of colon cancer in vivo and enhanced the anti-colon cancer effect of cisplatin through reducing tumor volume and weight.Overexpression of LINC00261 in SW480/DDP cells inhibited the survival rate. |
| Pubmed ID | 29267503 |
| Year | 2017 |
| Title | Long non-coding RNA LINC00261 sensitizes human colon cancer cells to cisplatin therapy. |
External Links
| Links for LINC00261 | GenBank HGNC NONCODE |
| Links for colon cancer | OMIM COSMIC |